Key result
In mild heart failure with left bundle-branch block and moderate renal dysfunction, CRT-D reduced death with a 14% absolute risk reduction (HR 0.66; 95% CI 0.44-1.00; P=0.05).
Why the study?
Does cardiac resynchronization therapy with defibrillator reduce death and heart failure events in patients with mild heart failure and moderate renal dysfunction?
RCT (n=1,820)
Yes
Does cardiac resynchronization therapy with defibrillator reduce death and heart failure events in patients with mild heart failure and moderate renal dysfunction?
Hazard Ratio: 0.66 (95% CI 0.44–1)
Absolute Risk Reduction: 14%
p-value: p=0.05
CRT-D provides significant long-term reduction in mortality and heart failure events in mild HF patients with LBBB, with the greatest absolute benefit observed in those with moderate renal dysfunction.
No takes yet. Share an insight, caveat, or question.
May support CRT-D in this subgroup; hypothesis-generating and requires prospective validation.
Daimee et al. (2015) conducted an RCT in Mild heart failure (n=1,820). Cardiac resynchronization therapy with defibrillator was evaluated on Death (HR 0.66, 95% CI 0.44-1.00, p=0.05). In mild heart failure with left bundle-branch block and moderate renal dysfunction, CRT-D reduced death with a 14% absolute risk reduction (HR 0.66; 95% CI 0.44-1.00; P=0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: